ArticleEquine veterinary journal2023
Predictors of laminitis development in a cohort of nonlaminitic ponies.
Article in Equine veterinary journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 97 citations in OpenAlex.
- High molecular weight adiponectin as an adjunct biomarker for insulin dysregulation in equids.Journal of veterinary internal medicine · 2026Article
- Prevalence of insulin dysregulation in a sport horse population as determined by traditional and stall-side testing.Equine veterinary journal · 2026Article
- Efficacy and safety of canagliflozin in insulin dysregulated horses: a 4-week multi-arm, double-blind, randomized, clinical trial.Journal of veterinary internal medicine · 2026Article
- The Effect of Lipemia on Insulin and Adiponectin Measurement in Equine Blood Samples.Veterinary clinical pathology · 2026Article
- Effects of pasture consumption and obesity on insulin dysregulation and adiponectin concentrations in UK native-breed ponies.Equine veterinary journal · 2026Article
- A point-based laminitis risk scoring system and machine learning framework for prediction of laminitis in horses.Frontiers in veterinary science · 2026Article
- Equine Pituitary Pars Intermedia Dysfunction.Veterinary sciences · 2025Review
- Sodium-glucose transport protein 2 inhibitor use in the management of insulin dysregulation in ponies and horses.Journal of veterinary pharmacology and therapeutics · 2025Review
- Systemic absorption of triamcinolone acetonide is increased from intrasynovial versus extrasynovial sites and induces hyperglycemia, hyperinsulinemia, and suppression of the hypothalamic-pituitary-adrenal axis.Frontiers in veterinary science · 2024Article
- Development of a Web App to Convert Blood Insulin Concentrations among Various Immunoassays Used in Horses.Animals : an open access journal from MDPI · 2023Article
- Prevalence and risk factors for laminitis within the Norwegian pony breed Nordlandshest/Lyngshest.Acta veterinaria Scandinavica · 2023Article
- Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors.Open veterinary journal · 2023Article
- Effect of sirolimus on insulin dynamics in horses.Journal of veterinary internal medicine · 2023Article
- Predictors of laminitis development in a cohort of nonlaminitic ponies.Equine veterinary journal · 2023Article
- Article
- Evaluation of an Automated Fluorescence Enzyme Immunoassay for Quantification of Equine Insulin and Comparison to Five Other Immunoassays.Journal of veterinary internal medicineArticle
- Value of measuring markers of lipid metabolism in horses during an oral glucose test.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundQuantifying risk factors for laminitis development requires improvement.
objectivesTo identify the most useful physical examination, metabolic and management factors to predict laminitis development in client-owned, nonlaminitic ponies. STUDY
designProspective cohort study.
methodsPhysical examination, metabolic and management data were collected from a pony cohort 6 monthly for up to 4 years. Ponies were monitored for the development of laminitis. Metabolic data included basal plasma concentrations of ACTH ([ACTH]), adiponectin ([adiponectin]), triglycerides and glucose. Serum insulin concentrations ([insulin]) were measured in the unfasted basal state ([insulin]T0) and 60 minutes ([insulin]T60) after administration of corn syrup (0.3ml/kg). Separate multivariable Cox proportional-hazards models were developed for physical, management/signalment and metabolic data and later combined into two final models. Low-, medium- and high-laminitis risk categories were defined based on basal or T60 [insulin].
resultsOverall, 374 ponies (age 5-32 years) and 891 pony-years were included in the main analysis. Laminitis incidence (95% confidence interval (CI)) was 4.8 (3.5-6.5) cases/100 pony-years. Laminitis development was associated with numerous univariable factors. Significant (P < .05) factors retained in the final multivariable models included [insulin]T0, [insulin]T60, [adiponectin] and divergent hoof growth. [ACTH] was not independently associated with laminitis. Based on [Insulin]T0, low- (<21.6 µIU/ml), medium- (21.6-45.2 µIU/ml) and high-risk (>45.2 µIU/ml) categories encompassed 70, 20 and 10% of the population and had estimated 4-year laminitis incidences (95%CI) of 6 (2-9)%, 22 (10-33)% and 69 (48-82)% respectively. Based on [Insulin]T60 the low- (<53.4 µIU/ml), medium- (53.4-153 µIU/ml) and high-risk (≥153 µIU/ml) categories comprised 60, 30 and 10% of the population and had estimated 4-year laminitis incidences (95%CI) of 3 (0-6)%, 20 (10-29)% and 73 (52-84)% respectively. MAIN LIMITATIONS: Results may not apply to different insulin assays, geographical regions, breeds or management types.
conclusions[Insulin]T0 or [insulin]T60 best quantify the risk of future laminitis development in nonlaminitic ponies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.